10-K/A: Kaya Holdings Reports Discontinued Operations and Ongoing Concerns in Amended 10-K Filing

Kaya Holdings' amended 10-K filing reveals discontinued retail cannabis operations, a shift towards psychedelic medicine, and substantial doubt about the company's ability to continue as a going concern.

Summary

• Kaya Holdings, Inc. filed an amended 10-K report for the year ended December 31, 2024.
• The company discontinued its retail cannabis operations under the MJAI subsidiary during the first half of 2024.
• Kaya Holdings is shifting its focus to the development of its Psychedelic Medicine business, including The Sacred Mushroom facility in Portland, Oregon.
• The company incurred a net loss of $2,080,856 for the year ended December 31, 2024, compared to a net income of $1,609,697 in 2023.
• The report indicates a working capital deficiency of $8,035,323 and dependence on raising capital, raising substantial doubt about the company's ability to continue as a going concern.
• Management plans to address liquidity concerns through the sale of equity and debt securities, alliances, partnerships, and business transactions.
• The company issued common stock to officers, directors, and related parties for services rendered and to acquire equity interest in FDT Oregon 1 LLC.
• Kaya Holdings entered into multiple convertible note agreements, some of which include price adjustment provisions that require derivative accounting.
• The company is involved in a legal settlement requiring monthly payments of $300 for 18 months, followed by a balloon payment of $11,779.
• Subsequent to year-end, the company received an additional $235,000 from an institutional investor for a convertible promissory note.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the discontinued operations, net loss, working capital deficiency, and dependence on raising capital. However, the shift to psychedelic medicine and the additional funding provide some positive aspects.

Positives

• The company is shifting its focus to the Psychedelic Medicine business, which may offer new growth opportunities.
• The Sacred Mushroom facility in Portland, Oregon, is now open and administering psilocybin treatments.
• The company has net operating loss carryforwards of approximately $18,736,396 at December 31, 2024, which can be used to offset future taxable income.
• The company has secured additional funding of $235,000 from an institutional investor subsequent to year-end.

Negatives

• The company discontinued its retail cannabis operations, which was previously its primary revenue-generating subsidiary.
• The company incurred a net loss of $2,080,856 for the year ended December 31, 2024.
• The report indicates a working capital deficiency of $8,035,323, raising substantial doubt about the company's ability to continue as a going concern.
• The company is dependent on raising additional capital to fund its operations.
• The company has significant derivative liabilities associated with its convertible notes, totaling $2,497,275 at December 31, 2024.

Risks

• The company's ability to continue as a going concern is uncertain due to its working capital deficiency and dependence on raising capital.
• The company's plan of operations may not result in generating positive working capital in the near future.
• The company's success depends on its ability to successfully execute its business plan, which includes third-party financing and capital issuance.
• The company is subject to certain tax risks and treatments that could negatively impact its results of operations, including Section 280E of the Internal Revenue Code.
• The company is involved in a legal settlement requiring monthly payments, which could strain its financial resources.

Future Outlook

Management plans to address liquidity concerns through the sale of equity and debt securities, alliances, partnerships, and business transactions. The company intends to pursue the sale of MJAI and its related assets in the first quarter of 2025.

Industry Context

The company's shift from retail cannabis to psychedelic medicine reflects a broader trend in the industry, with increasing interest and investment in psychedelic therapies for mental health disorders. The regulatory landscape for cannabis and psychedelics is evolving, creating both opportunities and challenges for companies in these sectors.

Comparison to Industry Standards

• It is difficult to compare Kaya Holdings directly to industry standards due to its unique combination of cannabis and psychedelic medicine businesses.
• Comparable cannabis companies include Curaleaf, Trulieve, and Green Thumb Industries, which are larger and more established players in the retail cannabis market.
• Comparable psychedelic medicine companies include Atai Life Sciences, Compass Pathways, and MindMed, which are focused on developing and commercializing psychedelic therapies.
• Kaya Holdings' financial performance lags behind these industry leaders, reflecting its smaller size and ongoing challenges.

Legal Proceedings

• The Company reached a settlement agreement with P3 Distributing L.L.C. in connection with a lawsuit filed in the Marion County Circuit Court, Case No. 24CV08588.

Related Party Transactions

• The Board of Directors approved the issuance of 1,000,000 shares of common stock to FDT Oregon 1 LLC owners who are also the Companys related party to acquire equity interest of FDT Oregon 1 LLC.
• In 2019, the Company entered into amended consulting agreements with Tudog International Consulting, Inc. which provides CEO services to the Company through Craig Frank, an Officer of the Company and BMN Consultants, Inc. which provides business development and financial consulting services to the Company through William David Jones, a non-officer Consultant to the Company.

Stakeholder Impact

• Shareholders face uncertainty due to the company's financial challenges and dependence on raising capital.
• Employees in the discontinued retail cannabis operations have been affected by the closure of the business.
• Customers of the retail cannabis operations will no longer be served by the company.
• Suppliers and creditors may be impacted by the company's financial challenges and ability to meet its obligations.

Next Steps

• The company intends to pursue the sale of MJAI and its related assets in the first quarter of 2025.
• Management plans to continue developing its Psychedelic Medicine business, including The Sacred Mushroom facility.
• The company will need to secure additional financing to fund its operations and address its working capital deficiency.

Key Dates

Keywords

Kaya Holdings, discontinued operations, cannabis, psychedelic medicine, The Sacred Mushroom, going concern, convertible notes, derivative liabilities, financial statements, MJAI